Detalhe da pesquisa
1.
Impact of pretransplant minimal residual disease in patients with multiple myeloma and a very good partial response or better receiving autologous hematopoietic stem cell transplantation.
Cancer;
130(9): 1663-1672, 2024 May 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38127583
2.
Impact of revised International Staging System 2 risk stratification on outcomes of patients with multiple myeloma receiving autologous haematopoietic stem cell transplantation.
Br J Haematol;
204(5): 1944-1952, 2024 May.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38448009
3.
Idecabtagene vicleucel chimeric antigen receptor T-cell therapy for relapsed/refractory multiple myeloma with renal impairment.
Haematologica;
109(3): 777-786, 2024 Mar 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37731379
4.
Outcomes of young adults (aged ≤ 40 years) with newly diagnosed multiple myeloma after up-front autologous stem cell transplant.
Br J Haematol;
202(4): 866-873, 2023 08.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37376789
5.
Factors associated with refractoriness or early progression after idecabtagene vicleucel in patients with relapsed/refractory multiple myeloma: U.S. Myeloma Immunotherapy Consortium real world experience.
Haematologica;
2023 10 19.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37855036
6.
Single-agent lenalidomide maintenance after upfront autologous stem cell transplant for newly diagnosed multiple myeloma: The MD Anderson experience.
Am J Hematol;
98(10): 1571-1578, 2023 10.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37461327
7.
Outcomes of patients with limited-stage plasmablastic lymphoma: A multi-institutional retrospective study.
Am J Hematol;
98(2): 300-308, 2023 02.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36588409
8.
Phase I study protocol: NKTR-255 as monotherapy or combined with daratumumab or rituximab in hematologic malignancies.
Future Oncol;
17(27): 3549-3560, 2021 Sep.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34154392
9.
Age Is a Prognostic Factor for the Overall Survival of Patients with Multiple Myeloma Undergoing Upfront Autologous Hematopoietic Stem Cell Transplantation.
Biol Blood Marrow Transplant;
26(6): 1077-1083, 2020 06.
Artigo
em Inglês
| MEDLINE
| ID: mdl-31786242
10.
Impact of gender on outcomes of patients with multiple myeloma undergoing autologous Haematopoietic stem cell transplant.
Br J Haematol;
201(4): e37-e41, 2023 05.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36916461
11.
Feasibility of Lenalidomide Therapy for Persistent Chronic Lymphocytic Leukemia after Allogeneic Transplantation.
Biol Blood Marrow Transplant;
23(8): 1405-1410, 2017 Aug.
Artigo
em Inglês
| MEDLINE
| ID: mdl-28495642
12.
Clinical efficacy of sequencing CD38 targeting monoclonal antibodies in relapsed refractory multiple myeloma: A multi-institutional experience.
Am J Hematol;
97(7): E276-E280, 2022 07.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35472167
13.
Outcomes of lenalidomide retreatment with novel triplet regimens in patients with multiple myeloma progressing on lenalidomide-based maintenance therapy.
Br J Haematol;
193(3): e23-e26, 2021 05.
Artigo
em Inglês
| MEDLINE
| ID: mdl-33748943
14.
Black multiple myeloma patients undergoing upfront autologous stem cell transplant have similar survival outcomes compared to Whites: A propensity-score matched analysis.
Am J Hematol;
96(12): E455-E457, 2021 12 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34559916
15.
Outcomes of autologous stem cell transplantation in Waldenström's macroglobulinemia.
Ann Hematol;
98(9): 2233-2235, 2019 Sep.
Artigo
em Inglês
| MEDLINE
| ID: mdl-31243571
16.
Long-term durable efficacy of autologous stem cell transplantation in POEMS syndrome.
Am J Hematol;
94(3): E72-E74, 2019 03.
Artigo
em Inglês
| MEDLINE
| ID: mdl-30548467
17.
Melphalan-based autologous transplant in octogenarian multiple myeloma patients.
Am J Hematol;
94(1): E2-E5, 2019 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-30300461
18.
Practical Aspects of Immunotherapy: A Report from the 20th International Myeloma Society (IMS) Annual Meeting.
Clin Lymphoma Myeloma Leuk;
24(6): 350-357, 2024 Jun.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38627181
19.
Management and Outcomes of Patients with Refractory Solitary Plasmacytoma after Treatment with Definitive Radiation Therapy.
Int J Radiat Oncol Biol Phys;
119(1): 193-199, 2024 May 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38070713
20.
Novel Anti-B-cell Maturation Antigen Alpha-Amanitin Antibody-drug Conjugate HDP-101 Shows Superior Activity to Belantamab Mafodotin and Enhanced Efficacy in Deletion 17p Myeloma Models.
Res Sq;
2024 Jan 11.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38260385